Wheelhouse Capital Partners

About The Fund

Wheelhouse Capital Partners, which can be identified as Aglaia Oncology Funds based on the information given, is a specialized venture capital fund headquartered in Businesspark Berg en Bosch, Prof. Bronkhorstlaan 10 building 92, Bilthoven, NL-3723 MB, Netherlands. They focus on investing in the field of oncology drug development, by channeling their resources into early-stage ventures with a vision of building tomorrow's industry leaders. Their investment thesis revolves around the idea that by backing breakthrough inventions at an early stage, they can significantly influence the landscape of cancer treatment. The Aglaia team holds impressive credentials, with decades of experience in both cancer research and oncology drug development, marking them as seasoned veterans in starting biotech companies that focus specifically on creating cancer drugs. They are deeply committed to setting strategic directions in close collaboration with innovators and entrepreneurs, playing a hands-on role in developing R&D plans that span from early screening and feasibility studies up to clinical trials. Through their Oncology Funds I, II, and Growth Opportunity Funds, Aglaia has successfully invested in 12 early stage companies, 6 of which they have found themselves, and have notably been involved in the development of more than 100 oncology products. Their continuous strategic and operational involvement ensures a higher success rate in transitioning early-stage companies to clinical-stage entities, thereby de-risking and maturing these companies until they become attractive for licensing, acquisitions, or IPOs. The firm is inspired by the Greek goddess Aglaia, symbolizing their commitment to health and well-being by developing innovative cancer therapies with potentially higher cure rates and fewer side effects. Aglaia's current portfolio includes a variety of innovative projects in the field of cancer research and treatment. In addition to financial returns, they place a strong emphasis on socio-economic impact, collaborating with social impact consultancy firms to measure and report the value their investments add to society and patients' lives.